Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Mycolog® II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1...
-
Nov 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Exalgo® 32mg extended release tablets (hydromorphone HCl) C-II. Exalgo® 32mg extended release...
-
Nov 21, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its Active Pharmaceutical Ingredient (API) business based in Israel to SK...
-
Nov 10, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Stifel Healthcare Conference at 8:45 AM EST on Tuesday,...
-
Nov 9, 2017
Delivered third quarter 2017 GAAP ("reported") net sales of $1.2 billion, reported net income of $45 million and reported diluted earnings per share ("EPS") of $0.31 compared to a loss per share...
-
Nov 2, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on December 19, 2017 to shareholders of record on...
-
Nov 2, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol...
-
Oct 26, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2017 financial results on Thursday, November 9, 2017. The Company will also host a conference call...
-
Oct 26, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) brought by...
-
Oct 24, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol...
-
Sep 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has initiated shipments to retail customers of the first-to-market over-the-counter ("OTC") store brand equivalent of Nexium® 24HR...
-
Sep 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Sep 18, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya® (clindamycin phosphate and...
-
Aug 30, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Wells Fargo Healthcare Conference at 4:10 PM EDT on...
-
Aug 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR...
-
Aug 16, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Aug 10, 2017
Delivered second quarter 2017 GAAP ("reported") net sales of $1.2 billion CHC Americas segment reported nets sales of $605 million compared to $630 million last year, lower by 4%; Adjusted net...
-
Aug 8, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on September 12, 2017 to shareholders of record on...
-
Aug 4, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Mirvaso® (brimonidine) topical gel...
-
Jul 31, 2017
Perrigo Company plc (NYSE; TASE: PRGO) and its co-development partner Aveva Drug Delivery Systems, Inc., an Apotex Company, today announced the prescription pharmaceutical launch of scopolamine...
-
Jul 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter 2017 financial results on Thursday, August 10, 2017. The Company will conduct a conference call at...
-
Jul 19, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jul 17, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic...
-
Jul 17, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jul 17, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Dymista® (azelastine hydrochloride and fluticasone propionate) nasal spray...
-
Jul 5, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and...
-
Jun 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products®", today announced that the Company's Board of Directors has retained Spencer Stuart,...
-
Jun 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%)...
-
Jun 19, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched hydrocodone bitartrate and homatropine methylbromide oral solution. Hydrocodone bitartrate and homatropine methylbromide oral...
-
Jun 14, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the reference yield and total consideration for each series of notes subject to the previously announced cash...
-
Jun 14, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Jeff Needham, Perrigo's Executive Vice President and President, Consumer Healthcare Americas, will present at the Oppenheimer 2017...
-
Jun 14, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the early tender results as of 5:00 p.m., New York City time, June 13, 2017 (the "Early Tender Deadline") for...
-
Jun 5, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the forthcoming retirement of Chief Executive Officer John T....
-
Jun 2, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo CEO John T. Hendrickson will present at the Jefferies 2017 Healthcare Conference at 3:00 PM EDT on Tuesday, June 6, 2017....
-
May 31, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today that it and Perrigo Finance Unlimited Company, its wholly-owned finance subsidiary ("Perrigo Finance"), have...
-
May 30, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Wednesday, May 31 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer,...
-
May 30, 2017
Delivered first quarter 2017 GAAP ("reported") net sales of $1.2 billion, led by consumer-facing businesses net sales of $958 million Realized first quarter reported net income of $72 million and...
-
May 22, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Tuesday, May 23 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer, to...
-
May 22, 2017
Comprehensive Form 10-K reflects accounting treatment of historical Tysabri® royalty stream as a financial asset No impact on net cash flows or previously closed sale of Tysabri® Revised...
-
May 8, 2017New Directors Nominated by Starboard in Accordance With Previously Announced Agreement
Perrigo Company plc (NYSE; TASE: PRGO) today announced the appointment of Rolf A. Classon and Adriana Karaboutis to the Company's Board of Directors. Pursuant to the agreement with Starboard Value...
-
May 3, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on June 13, 2017 to shareholders of record on May 26, 2017.
-
May 2, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that search warrants were executed at the Company's corporate offices associated with an ongoing investigation by the U.S. Department of...
-
Apr 25, 2017- Tysabri® historical royalty stream determined to be a financial asset; Company to file 2016 Form 10-K, including restated fiscal 2014, fiscal 2015 and transition period 2015 audited financials and certain quarterly financial information as soon as practical
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today announced that the Company's Board of Directors, after consultation with management...
-
Mar 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has completed the divestiture of its rights to the royalty stream...
-
Mar 16, 2017- Continues to work with independent auditor, and expects to file its Form 10-K as soon as practical
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "We continue to make progress with our independent auditor, Ernst & Young...
-
Mar 8, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the first-to-market launch of the over-the-counter ("OTC") store brand equivalent to Women's Rogaine® 5% minoxidil foam (minoxidil topical...
-
Mar 7, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "As previously discussed, in connection with a review for the announced...
-
Mar 1, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application referencing Eli Lilly and...
-
Feb 27, 2017
Delivered preliminary unaudited calendar year 2016 record reported net sales of $5.6 billion and adjusted net sales of $5.5 billion Unaudited calendar year 2016 preliminary reported loss per...
-
Feb 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has signed a definitive agreement to divest its rights to the...
-
Feb 27, 2017Appoints Ron Winowiecki as Acting CFO Following Resignation of Judy L. Brown
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ron Winowiecki, Senior Vice President, Business Finance, has...
-
Feb 21, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on March 21, 2017 to shareholders of record on March 3,...
-
Feb 17, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral...
-
Feb 14, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release financial results for its fourth quarter and calendar year 2016 on Monday, February 27, 2017 at approximately 4:00 p.m....
-
Feb 7, 2017
Perrigo Company plc (NYSE; TASE: PRGO) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for clindamycin, benzoyl peroxide...
-
Feb 7, 2017Company to Reconstitute Board with Five New Independent Directors
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has entered into an agreement with Starboard Value LP ("Starboard"), which owns approximately 6.7 percent of Perrigo's shares,...
-
Jan 24, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received U.S. Food and Drug Administration approval for its first-to-file Abbreviated New Drug Application referencing Taro...
-
Jan 10, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has changed its reporting segments to better align with the Company's organizational structure. Beginning with the fourth quarter of...